Arabic Arabic English English French French German German
dark

NEUVOGEN Appoints Cellular Immune Therapy Expert, Dr. Jack Bui to its Scientific Advisory Board

 NEUVOGEN, an immunoncology company, is pleased to announce the appointment of Dr. Jack Bui to its Scientific Advisory Board (“SAB”) effective August 30, 2021 . Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

FDA Orphan Drug Approval: Octapharma’s Octagam® 10% Receives 7 Years of Market Exclusivity for Adult Dermatomyositis

Next Post

BioIVT Launches Human AB Serum Product Line to Facilitate Cell and Gene Therapy Development

Related Posts
Total
0
Share